印度启动了PRIP计划,从2025年10月1日起,以5 000克朗的资金资助300个制药和医疗研发项目。 India launches PRIP scheme with ₹5,000 crore to fund 300 pharma and medtech R&D projects starting Oct. 1, 2025.

印度启动了PRIP计划,拨款5 000卢比用于支助大约300个药剂和医疗研发项目,总价值约11 000卢比。 India has launched the PRIP scheme, allocating Rs 5,000 crore to support around 300 pharma and medtech R&D projects with a total value of about Rs 11,000 crore. 从2025年10月1日开始,初创企业和微小中型企业可以申请早期项目,资金最多为5卢比,第一个1卢比为100%,其余为50%。 Starting October 1, 2025, startups and MSMEs can apply for early-stage projects with up to Rs 5 crore in funding—100% for the first Rs 1 crore and 50% for the rest. 后阶段项目可能得到最多100卢比,占费用的35%,对诸如罕见疾病、抗微生物抗药性和大流行病病原体等战略领域提供最多50%的支助。 Later-stage projects may receive up to Rs 100 crore, covering 35% of costs, with up to 50% support for strategic areas like rare diseases, antimicrobial resistance, and pandemic pathogens. 申请通过一个政府门户网站以数字方式提交,以促进创新和健康保障。 Applications are submitted digitally via a government portal to boost innovation and health security.